Table of Contents
Understanding Cystic Fibrosis-Related Diabetes: A Unique Complication
Cystic fibrosis-related diabetes (CFRD) is one of the most common complications of CF in adults, affecting nearly 30% of adults with CF. More than 40% of adults with CF ages 50 to 60 years have CFRD, making it an increasingly important concern as people with cystic fibrosis live longer thanks to advances in treatment. This condition represents a significant challenge for both patients and healthcare providers, as it adds another layer of complexity to an already demanding disease management regimen.
While it shares features of type 1 and type 2 diabetes, CFRD is a distinct clinical entity. Understanding the unique characteristics of CFRD is essential for developing effective treatment strategies and improving outcomes for individuals living with cystic fibrosis.
The Pathophysiology of CFRD
The pathophysiology of cystic fibrosis-related diabetes is complex and not completely understood, believed to be multifactorial with both a functional and structural component. Functional abnormalities seen in CFRD stem from a defect in the cystic fibrosis transmembrane regulator (CFTR) gene, which gets expressed in pancreatic beta-cells where its exact role remains unknown, though animal models suggest that CFTR has an intrinsic role in insulin secretion.
In addition to functional impairment of the beta cell, structural damage to pancreatic islet cells also occurs due to the defective CFTR protein, which is present in the ductal epithelial cells of the pancreas. The thick, sticky mucus characteristic of cystic fibrosis causes scarring and fibrosis of the pancreas over time, progressively destroying the insulin-producing beta cells. This dual mechanism—both functional impairment and structural destruction—makes CFRD particularly challenging to manage.
It is primarily caused by insulin insufficiency, although fluctuating levels of insulin resistance related to acute and chronic illness also play a role. This means that people with CFRD experience both inadequate insulin production (similar to type 1 diabetes) and periods of insulin resistance (similar to type 2 diabetes), particularly during illness, when taking corticosteroids, or during pregnancy.
Clinical Presentation and Symptoms
The majority of individuals with CFRD present with no obvious clinical symptoms at the time of diagnosis, and polyuria and polydipsia as presenting symptoms are less common in CFRD than in other forms of new-onset diabetes. This silent nature of CFRD makes regular screening critically important for early detection and intervention.
Failure to maintain or gain weight irrespective of adequate nutrition may present as the first indication of CFRD, and growth deceleration and weight loss generally precede the manifestation of CFRD by several years in the pediatric patient population with CF. These subtle signs can easily be overlooked or attributed to CF itself, which is why healthcare providers must maintain a high index of suspicion.
Impact on Health Outcomes
The additional diagnosis of CFRD has a negative impact on pulmonary function and survival in CF, and this risk disproportionately affects women. The relationship between CFRD and lung function is bidirectional—poor glycemic control can worsen lung function, while pulmonary exacerbations can worsen blood sugar control, creating a vicious cycle that must be carefully managed.
It is important to manage CFRD to prevent complications, such as nerve damage, retinal (eye) damage, kidney damage, and to help prevent weight loss, lung exacerbations and infections, and improve survival. Early diagnosis and proper management can significantly slow the rate of pulmonary decline and improve overall health outcomes.
Interestingly, in contrast to patients with other types of diabetes, there are no documented cases of death from atherosclerotic vascular disease in patients with CFRD, despite the fact that some now live into their sixth and seventh decades. This unique characteristic suggests that CFRD may have different long-term cardiovascular implications compared to traditional forms of diabetes, though this is an area requiring further research as the CF population continues to age.
Screening and Diagnosis of CFRD
Early detection of CFRD is crucial for preventing complications and maintaining optimal health in people with cystic fibrosis. As early cystic fibrosis-related diabetes (CFRD) may be clinically silent, these guidelines highlight the importance of regular screening. The asymptomatic nature of early CFRD means that systematic screening protocols are essential for identifying affected individuals before significant complications develop.
Current Screening Recommendations
Annual screening for CFRD should begin by ten years of age in all individuals with cystic fibrosis. This recommendation is based on the increasing prevalence of CFRD with age and the evidence that early intervention can improve outcomes. The oral glucose tolerance test (OGTT) remains the gold standard for screening, as it can detect abnormal glucose metabolism before fasting glucose levels become elevated.
Additional screening methods such as urine glucose testing, random plasma glucose measurements, fructosamine testing, and monitoring of hemoglobin A1c levels are not recommended due to their low sensitivity. These tests may miss early stages of glucose intolerance, potentially delaying diagnosis and treatment. The OGTT, while more time-consuming and burdensome for patients, provides the most comprehensive assessment of glucose metabolism.
Diagnostic Criteria
At baseline health, the standard American Diabetes Association criteria are used to make the diagnosis of CFRD: 2-hour plasma glucose level greater than or equal to 200 mg/dL on oral glucose tolerance testing, fasting plasma glucose greater than or equal to 126mg/dL, HgA1c greater than or equal to 6.5%, and/or random glucose greater than or equal to 200mg/dL with clinical symptoms. These criteria align with those used for other forms of diabetes but are applied in the specific context of cystic fibrosis.
During acute illness, the diagnostic criteria are slightly different. In a state of acute illness, a 2-hour postprandial plasma glucose level greater than or equal to 200 mg/dL or a fasting plasma glucose greater than or equal to 126mg/dL persists for 48 hours more are diagnostic. This distinction is important because stress hyperglycemia during illness is common in CF and does not necessarily indicate CFRD.
The Role of Continuous Glucose Monitoring
Continuous glucose monitoring (CGM) technology has been applied in research and clinical settings for insights into CFRD pathophysiology, and its use for early dysglycemia detection in the CF population is increasing. CGM devices provide real-time glucose readings throughout the day and night, offering a more comprehensive picture of glucose patterns than traditional fingerstick testing or even OGTT.
Technological advances in diabetes management, such as CGM and insulin delivery devices, along with an emerging role for predictive algorithms, have been explored in the management of CFRD, and a survey of 120 individuals with CF and family members found that the majority of people with CFRD and their caregivers have used CGM and hold a generally positive opinion of this technology. The acceptance and utility of CGM in the CF population represents a significant advancement in diabetes care for these patients.
CGM has been adopted into clinical care of people with CFRD based on studies that identified the utility of CGM to guide treatment decisions and documented sensitivity to identify expected glycaemic excursions during pulmonary exacerbations. This technology is particularly valuable during periods of illness when glucose control can be especially challenging.
Current Treatment Approaches for CFRD
Managing CFRD requires a multidisciplinary approach that addresses both the diabetes and the underlying cystic fibrosis. Management recommendations focus on insulin therapy and ongoing care by a team with knowledge of CF and diabetes, provided by a multidisciplinary team with knowledge of CF and diabetes. This specialized care is essential because CFRD has unique characteristics that differ from both type 1 and type 2 diabetes.
Insulin Therapy: The Cornerstone of Treatment
People with CF make less insulin, which can lead to CFRD, and insulin is the most common treatment for CFRD. Unlike type 2 diabetes, where oral medications are often the first-line treatment, insulin is typically necessary for CFRD because the primary problem is insulin deficiency rather than insulin resistance.
Various types of insulin are used in CFRD management, including rapid-acting, short-acting, intermediate-acting, and long-acting formulations. Lispro, aspart, and glulisine start working 15 to 25 minutes after they are taken. These rapid-acting insulins are particularly useful for controlling post-meal glucose spikes, which are common in CFRD.
The goal of insulin therapy in CFRD is not just to control blood sugar levels but also to promote anabolism—the building up of body tissues. Adequate insulin allows people with CF to maintain or gain weight, preserve muscle mass, and support overall nutritional status, all of which are critical for maintaining lung function and quality of life.
Emerging Role of GLP-1 Receptor Agonists
As the CF population lives longer and experiences changes in body composition, particularly with the advent of CFTR modulator therapies, the treatment landscape for CFRD is evolving. Since the introduction of CFTR modulators, people with CF are living longer and their symptoms are beginning to resemble those of the general population, with issues such as obesity, high cholesterol, and heart disease occurring more frequently, and being overweight or obese has not traditionally been a cause of insulin resistance in CF, but this is changing with CFTR modulators.
There are several brands of GLP-1 inhibitors on the market, including Victoza®, Bydureon®, Trulicity®, and Ozempic®, which are all drugs in this class, available in daily forms and weekly forms. In the past, these drugs have rarely been considered in CF because they cause significant weight loss. However, as more people with CF become overweight or obese, particularly those on highly effective CFTR modulators, GLP-1 receptor agonists may play an increasingly important role in CFRD management for select patients.
Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity has been documented in case series, suggesting that these medications may be appropriate for certain individuals with CFRD who are overweight or obese and experiencing insulin resistance.
Nutritional Management
The goal is to keep your blood sugar (also referred to as blood glucose) at normal — or near-normal — levels and to eat a balanced, healthy CF diet as recommended by your CF and diabetes care teams. Nutritional management in CFRD is particularly challenging because the dietary recommendations for CF (high-calorie, high-fat diet) can seem to conflict with traditional diabetes dietary advice.
However, people with CFRD should not restrict calories or fat intake in the way that people with type 2 diabetes might. Instead, the focus is on timing meals appropriately with insulin doses, choosing nutrient-dense foods, and ensuring adequate caloric intake to maintain weight and support lung function. Working with a dietitian who understands both CF and diabetes is essential for developing an appropriate meal plan.
CFTR Modulator Therapy: A Game-Changer for CF and CFRD
The development of CFTR modulator therapies represents one of the most significant advances in cystic fibrosis treatment in recent decades. These medications address the underlying cause of CF by improving the function of the defective CFTR protein, and they are having profound effects on the entire CF disease trajectory, including CFRD.
How CFTR Modulators Work
CFTR modulators changed the whole strategy to treat cystic fibrosis because they actually fix the disease’s root cause, the CFTR protein, with ivacaftor, lumacaftor, and a triple combination (elexacaftor/tezacaftor/ivacaftor, Trikafta) improving CFTR protein function based on the mutation chosen. These medications work through different mechanisms—some help the CFTR protein fold correctly, others help it reach the cell surface, and still others improve its function once it’s in place.
Over the last decade, CFTR-targeted therapies, termed modulators, have revolutionised the care of CF, with the latest commercially available generation of CFTR modulators, elexacaftor plus tezacaftor plus ivacaftor (ETI), projected to greatly enhance the life expectancy of eligible people with CF, rivalling that of the non-CF population. This dramatic improvement in life expectancy is reshaping the landscape of CF care and creating new considerations for long-term complications like CFRD.
Impact on Pancreatic Function and CFRD
The CF Foundation has funded research who are investigating the effect that the cystic fibrosis transmembrane conductance regulator (CFTR) protein has on the development of CFRD to find ways to treat it. Understanding how CFTR modulators affect pancreatic function and glucose metabolism is a critical area of ongoing research.
Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR, according to a small pilot study. This finding suggests that CFTR modulators may have direct beneficial effects on beta-cell function, potentially by improving the pancreatic environment or by directly affecting insulin secretion mechanisms.
While early findings suggest CFTR modulators may offer metabolic benefits and potentially delay or reduce the need for insulin therapy in children CFRD, current evidence is limited, and larger, pediatric-focused clinical trials with standardized glycemic outcomes are essential to determine the long-term efficacy and safety of CFTRm in managing or preventing CFRD. The potential for CFTR modulators to prevent or delay CFRD is exciting, but more research is needed to fully understand their long-term effects on glucose metabolism.
Current evidence indicates that CFTR modulators hold potential to positively affect glucose metabolism in cystic fibrosis, particularly when introduced before significant pancreatic β-cell loss occurs. This suggests that early initiation of CFTR modulator therapy may be important for preserving pancreatic function and preventing or delaying CFRD.
Changing Clinical Landscape
With the advent of highly effective modulator therapies (HEMT), patients with CF are living longer and healthier lives, and consequently, CFRD and its microvascular complications are rising in prominence, becoming one of the most urgent clinical concerns. This paradox—that successful treatment of CF is leading to increased prevalence of CFRD—highlights the need for continued research and improved management strategies.
New developments in the form of highly effective modulators have transformed the landscape of cystic fibrosis (CF) care and life expectancy, and as CFRD is one of the most common complications of CF, there is a growing and urgent need to better understand how to optimise CFRD diagnosis and management across the continuum. The CF care community is actively working to address these evolving needs.
Emerging Treatments and Innovative Therapies for CFRD
As our understanding of CFRD pathophysiology deepens and technology advances, new treatment approaches are emerging that offer hope for improved management and potentially even prevention of this complication.
Inhaled Insulin Formulations
Inhaled insulin represents an innovative approach to insulin delivery that could be particularly beneficial for people with CF, who already have extensive experience with inhaled medications. While inhaled insulin products have been developed for the general diabetes population, their application in CFRD is an area of active investigation.
The potential advantages of inhaled insulin for CFRD include reduced injection burden (important for people already managing multiple daily CF treatments), rapid onset of action for controlling post-meal glucose spikes, and potentially improved adherence. However, concerns about pulmonary safety in a population with underlying lung disease have limited widespread adoption, and more research is needed to establish the safety and efficacy of inhaled insulin specifically in people with CF.
Advanced Insulin Delivery Systems
The survey indicated insulin pumps are less commonly used and generally have a lower acceptability rating by people with CFRD. Despite this, insulin pump therapy and automated insulin delivery systems (also known as artificial pancreas systems or closed-loop systems) represent important technological advances that may benefit select individuals with CFRD.
These systems combine continuous glucose monitoring with automated insulin delivery, adjusting insulin doses in real-time based on glucose levels. For people with CFRD who experience significant glucose variability, particularly during illness or with variable meal timing, these systems could provide improved glucose control with reduced burden. However, the complexity of adding another device to an already demanding treatment regimen is a significant consideration.
Gene Therapy and Gene Editing
Gene editing technologies, such as CRISPR-Cas9, could lead to a point where completely curative treatments for CF are on the horizon. While gene therapy for CF is primarily focused on correcting the CFTR defect in lung tissue, successful gene correction could potentially have beneficial effects on pancreatic function as well.
Trials on clinical gene editing are still in their infancy, but so far, preliminary results indicate that CRISPR-Cas9 could successfully repair CFTR mutations in vitro, with the next challenge being to bring preclinical trials into safe, effective clinical applications. If gene therapy can be successfully applied to correct CFTR mutations before significant pancreatic damage occurs, it could potentially prevent CFRD altogether.
Gene replacement therapy would involve replacing functional CFTR genes within affected cells, thus providing a long-term basis for treating patients with CF, and scientists are currently working on inhaled gene therapy delivery that would directly administer corrective genetic material to the lung. While pancreatic gene therapy faces additional challenges due to the organ’s location and the extent of damage that may already be present, it remains an area of interest for future research.
Stem Cell Therapy and Pancreatic Regeneration
Stem cell therapy represents a potentially revolutionary approach to treating CFRD by regenerating damaged pancreatic tissue. The concept involves using stem cells to replace or regenerate insulin-producing beta cells that have been destroyed by the disease process. While this approach is still largely in the preclinical research phase, it holds significant promise for the future.
Several strategies are being explored, including transplantation of stem cell-derived beta cells, stimulation of endogenous pancreatic stem cells to regenerate beta cells, and creation of bioengineered pancreatic tissue. The challenges are significant—ensuring that regenerated cells function properly, protecting them from the ongoing inflammatory and fibrotic processes in the CF pancreas, and achieving long-term engraftment and function. However, advances in stem cell technology and tissue engineering are bringing these approaches closer to clinical reality.
Anti-Inflammatory and Immunomodulatory Therapies
Chronic inflammation plays a significant role in the pathogenesis of both CF and CFRD. Anti-inflammatory therapies are being investigated to decrease the chronic lung inflammation that typifies CF and may slow the further progression of the disease. While these therapies are primarily aimed at lung disease, reducing systemic inflammation could potentially have beneficial effects on pancreatic function and glucose metabolism as well.
Therapies that modulate the immune response or reduce inflammation in the pancreas could potentially slow the progression of beta-cell destruction and preserve insulin secretion. This is an area where research in other forms of diabetes, particularly type 1 diabetes, may provide insights applicable to CFRD.
Cutting-Edge Research in CFRD
Research into CFRD is expanding rapidly, driven by the recognition that this complication significantly impacts health outcomes and quality of life for people with CF. During plenary 2 of the 2024 North American Cystic Fibrosis Conference, speakers focused on recent advances in CFRD research, including emerging diabetes technologies and new treatment strategies. Multiple research initiatives are underway to improve our understanding of CFRD and develop better approaches to prevention and treatment.
Biomarker Discovery and Early Detection
One of the most promising areas of CFRD research involves identifying biomarkers that can predict who will develop CFRD and when. Some of the key questions researchers seek to answer include: What are the risk factors associated with developing CFRD? Understanding these risk factors could enable more targeted screening and earlier intervention.
Known risk factors for CFRD include female sex, advancing age, lung function, liver disease, steroid treatment, family history of T2D, and genetic factors including both the CFTR gene and other modifier genes. However, these risk factors don’t fully explain why some people develop CFRD while others don’t, even with similar CFTR mutations and disease severity.
Researchers are investigating various potential biomarkers, including genetic markers, inflammatory markers, markers of beta-cell stress or dysfunction, and metabolic markers. A prospective longitudinal study conducted on children with CF between the ages of 6 and 9 years demonstrated that impaired glucose tolerance (IGT) and indeterminate glycemia (INDET) conditions predict risk of developing CFRD during adolescence. This suggests that early glucose abnormalities, even before CFRD diagnosis, may serve as important predictive markers.
The goal is to identify individuals at highest risk for CFRD before significant beta-cell loss occurs, when interventions might be most effective at preventing or delaying disease onset. This could enable a more personalized approach to CFRD screening and prevention.
Genetic Studies and Modifier Genes
Among contributors to the development of CFRD, in addition to CFTR genotype, there are other genetic factors related and not related to type 2 diabetes, and this review presents an overview of the current understanding on genetic factors associated with glucose metabolism abnormalities in CF. Understanding the genetic basis of CFRD susceptibility could lead to better risk prediction and potentially new therapeutic targets.
While the CFTR mutation itself is the primary genetic factor in CF, modifier genes—genes that influence disease severity and complications—play an important role in determining who develops CFRD. Some of these modifier genes are the same genes associated with type 2 diabetes risk in the general population, while others may be specific to the CF context.
Genome-wide association studies (GWAS) and other genetic research approaches are being used to identify these modifier genes. Once identified, they could be used to develop genetic risk scores that help predict CFRD risk, and they may also reveal new biological pathways that could be targeted therapeutically.
Microbiome Research
The gut microbiome—the community of bacteria and other microorganisms living in the digestive tract—has emerged as an important factor in many aspects of health and disease, including glucose metabolism and diabetes. People with CF have altered gut microbiomes due to the disease itself, frequent antibiotic use, and other factors, and researchers are investigating whether these microbiome changes contribute to CFRD development.
Studies have shown that the gut microbiome can influence insulin sensitivity, inflammation, and even beta-cell function through various mechanisms, including production of metabolites that affect glucose metabolism, modulation of the immune system, and effects on gut barrier function. In CF, the disrupted microbiome may contribute to insulin resistance and other metabolic abnormalities.
Research is exploring whether microbiome-targeted interventions—such as probiotics, prebiotics, dietary modifications, or even fecal microbiota transplantation—could help prevent or manage CFRD. While this research is still in early stages, it represents an innovative approach that could complement existing CFRD treatments.
Clinical Trials of Early Intervention
A critical question in CFRD research is whether early intervention—treating glucose abnormalities before they meet criteria for CFRD diagnosis—can prevent or delay disease progression and improve outcomes. Insulin for early glycaemic abnormality in children with cystic fibrosis without cystic fibrosis-related diabetes (CF-IDEA) was a randomized controlled trial examining this question.
Do nondiabetic CF patients with abnormal glucose tolerance benefit from diabetes therapy and, if so, what method of treatment has the greatest impact on nutritional and pulmonary status? This remains one of the most pressing research questions in CFRD. If early intervention proves beneficial, it could fundamentally change the approach to CFRD screening and management, shifting from treating established disease to preventing it.
Clinical trials are also investigating optimal treatment strategies for established CFRD, including comparisons of different insulin regimens, the role of newer diabetes medications, and the impact of intensive glucose control on CF-specific outcomes like lung function and nutritional status.
Understanding CFRD Mechanisms
What are the mechanisms by which CFRD impacts pulmonary function and survival in CF? This fundamental question drives much of the research in this field. Understanding these mechanisms could reveal new therapeutic targets and help optimize treatment strategies.
Several mechanisms have been proposed, including the catabolic effects of insulin deficiency (leading to muscle wasting and weight loss), the impact of hyperglycemia on immune function (increasing infection risk), direct effects of glucose on airway surface liquid and mucus properties, and systemic inflammatory effects. Research is working to determine which of these mechanisms are most important and how they can be targeted therapeutically.
Structural abnormalities in islets from very young children with cystic fibrosis may contribute to cystic fibrosis-related diabetes. This finding suggests that pancreatic abnormalities may be present very early in life, even before clinical manifestations of CFRD appear. Understanding these early changes could provide insights into disease pathogenesis and identify new opportunities for early intervention.
The Multidisciplinary Approach to CFRD Care
Effective management of CFRD requires coordination among multiple healthcare providers, each bringing specialized expertise to address different aspects of this complex condition. If you are diagnosed with CFRD, your CF care team will need to include an endocrinologist (a doctor with special training in the treatment of diabetes) and certified diabetes educators. This multidisciplinary approach is essential for providing comprehensive, coordinated care.
The CF Care Team
The core CF care team typically includes pulmonologists, nurses, respiratory therapists, dietitians, social workers, and pharmacists, all with expertise in cystic fibrosis. When CFRD develops, this team must expand to include diabetes specialists who understand the unique aspects of CFRD and how diabetes management intersects with CF care.
Coordination is critical because treatment decisions for one condition can affect the other. For example, corticosteroids used to treat pulmonary exacerbations can worsen glucose control, while aggressive insulin therapy during illness must be balanced against the risk of hypoglycemia. The care team must work together to optimize both CF and diabetes management.
Specialized Training and Expertise
To meet the growing demand for physicians who are trained to address the unique needs of people with CFRD, we created the Emerging Leaders in CF Endocrinology (EnVision) Program, which funds training and mentorship for physicians to develop expertise in the endocrinologic care of people with CF, and EnVision members share knowledge and resources to improve care and treatment of CFRD. This program recognizes that CFRD requires specialized knowledge that goes beyond general diabetes care.
Healthcare providers caring for people with CFRD need to understand not only diabetes management but also how CF affects glucose metabolism, how CF treatments impact diabetes, and how to balance the sometimes competing demands of managing both conditions. Training programs like EnVision are helping to build this specialized workforce.
Patient and Family Education
Education is a cornerstone of effective CFRD management. People with CFRD and their families need to understand blood glucose monitoring, insulin administration, carbohydrate counting, recognizing and treating hypoglycemia, managing glucose during illness, and how diabetes fits into their overall CF care plan.
A CFRD diagnosis can have negative emotional effects, and many people with CF express frustration at having another long-term condition that takes time and effort to manage. This emotional burden is real and significant. Coping with a new diagnosis like this can be difficult, but discussing it with your CF or diabetes care team may help, and you may also find help through CF Peer Connect, a one-to-one peer support program for people with cystic fibrosis and their family members age 16 and older, where you can talk with and learn from someone who has gone through similar experiences.
Peer support and mental health services are important components of comprehensive CFRD care. The psychological impact of managing both CF and diabetes should not be underestimated, and addressing mental health needs is essential for optimal outcomes.
Special Considerations in CFRD Management
Managing CFRD involves several unique considerations that distinguish it from other forms of diabetes. Understanding these special circumstances is essential for providing optimal care.
Glucose Management During Pulmonary Exacerbations
Pulmonary exacerbations—periods of worsening lung symptoms requiring intensified treatment—are common in CF and present particular challenges for glucose management. During exacerbations, insulin resistance typically increases due to inflammation and stress, while appetite may decrease, creating a difficult balancing act for glucose control.
Corticosteroids, often used to treat exacerbations, can dramatically worsen glucose control. Insulin requirements may increase substantially during this time, and more frequent glucose monitoring is essential. Some people who don’t normally require insulin may need it temporarily during exacerbations.
The relationship between glucose control and pulmonary outcomes during exacerbations is bidirectional—poor glucose control can impair immune function and prolong recovery, while the exacerbation itself worsens glucose control. Aggressive glucose management during these periods is important for optimizing recovery.
Nutritional Challenges
Nutrition in CFRD requires a delicate balance. People with CF typically need high-calorie, high-fat diets to maintain weight and support lung function, while traditional diabetes dietary advice emphasizes calorie control and fat limitation. This apparent conflict must be carefully navigated.
In CFRD, the priority is maintaining adequate nutrition and weight. Calorie restriction is generally not appropriate, and people with CFRD should continue to follow high-calorie CF dietary recommendations. Instead of restricting food intake, the focus is on matching insulin doses to carbohydrate intake and choosing nutrient-dense foods.
Many people with CF require supplemental nutrition through gastrostomy tubes, particularly overnight. Managing glucose during continuous tube feedings requires special insulin strategies, and this is an area where the expertise of a CF dietitian and diabetes specialist is particularly valuable.
Exercise and Physical Activity
Exercise is important for both CF (helping with airway clearance and maintaining lung function) and diabetes (improving insulin sensitivity and glucose control). However, exercise in CFRD requires careful planning to prevent hypoglycemia while still gaining the benefits of physical activity.
People with CFRD need to learn how to adjust insulin doses and carbohydrate intake around exercise, monitor glucose before, during, and after activity, and recognize and treat exercise-induced hypoglycemia. The type, intensity, and duration of exercise all affect glucose levels, and individuals must learn through experience how their body responds.
Airway clearance techniques, which are a form of physical activity performed multiple times daily by people with CF, can also affect glucose levels and should be considered in diabetes management planning.
Pregnancy and CFRD
Pregnancy in women with CF and CFRD requires specialized care from a high-risk obstetrics team familiar with both conditions. Glucose control becomes even more critical during pregnancy, as hyperglycemia can affect fetal development. At the same time, pregnancy increases insulin resistance, often requiring substantial increases in insulin doses.
Women with CF who don’t have CFRD before pregnancy may develop gestational diabetes at higher rates than the general population. Close monitoring throughout pregnancy is essential, and some women may require insulin therapy during pregnancy even if they don’t need it at other times.
Pregnancy also places additional demands on the respiratory system, which can be challenging for women with CF. Coordinating CF care, diabetes management, and obstetric care requires a highly coordinated multidisciplinary approach.
Microvascular Complications
Like other forms of diabetes, CFRD can lead to microvascular complications including retinopathy (eye damage), nephropathy (kidney damage), and neuropathy (nerve damage). However, the prevalence and progression of these complications in CFRD may differ from other types of diabetes.
Regular screening for these complications is important, following similar guidelines as for other forms of diabetes. However, interpreting screening results can be complicated by CF-related factors. For example, kidney function may be affected by CF-related factors such as frequent antibiotic use, independent of diabetes-related kidney disease.
The long-term risk of microvascular complications in CFRD is an area of ongoing research, particularly as people with CF live longer. Understanding this risk is important for determining appropriate screening intervals and treatment targets.
The Future of CFRD Management: Personalized Medicine and Precision Approaches
The future of CFRD care lies in increasingly personalized approaches that take into account individual genetic factors, disease characteristics, and treatment responses. As our understanding of CFRD pathophysiology deepens and new technologies emerge, treatment strategies are becoming more sophisticated and tailored to individual needs.
Precision Medicine Approaches
Precision medicine—tailoring treatment to individual characteristics—is increasingly important in CFRD management. This includes considering CFTR genotype, modifier genes, metabolic phenotype, and individual treatment responses when making therapeutic decisions.
For example, people with certain CFTR mutations may respond differently to CFTR modulators in terms of pancreatic function and CFRD risk. Understanding these genotype-phenotype relationships can help predict who is most likely to benefit from specific interventions and when treatment should be initiated.
Metabolic phenotyping—detailed characterization of an individual’s glucose metabolism patterns—can also guide treatment decisions. Some people with CFRD have primarily fasting hyperglycemia, others have mainly post-meal glucose spikes, and still others have glucose variability throughout the day. These different patterns may respond best to different insulin regimens or other interventions.
Predictive Analytics and Artificial Intelligence
Artificial intelligence and machine learning approaches are being applied to CFRD research and care in several ways. These technologies can analyze large datasets to identify patterns and predict outcomes, potentially improving risk prediction, treatment optimization, and complication prevention.
For example, machine learning algorithms can analyze continuous glucose monitoring data to predict hypoglycemia or hyperglycemia before it occurs, allowing for proactive interventions. These algorithms can also help identify optimal insulin doses based on individual patterns of glucose response, food intake, and activity.
Predictive models using clinical data, genetic information, and biomarkers may eventually be able to identify individuals at highest risk for CFRD years before diagnosis, enabling early preventive interventions. As these technologies mature, they have the potential to significantly improve CFRD outcomes.
Integration of Digital Health Technologies
Digital health technologies—including smartphone apps, wearable devices, telemedicine platforms, and connected medical devices—are transforming diabetes care, and these innovations are increasingly being applied to CFRD management.
Smartphone apps can help people with CFRD track glucose levels, insulin doses, carbohydrate intake, and symptoms, providing valuable data for treatment optimization. Some apps can analyze this data and provide personalized recommendations or alerts. Integration with continuous glucose monitors and insulin pumps allows for real-time data sharing with healthcare providers and automated insulin adjustments.
Telemedicine has become increasingly important, particularly for people with CF who may need to limit exposure to infections. Virtual visits can provide ongoing diabetes education, treatment adjustments, and support without requiring in-person clinic visits. This is particularly valuable for people who live far from specialized CF centers or during times when in-person visits are difficult.
Combination Therapies and Treatment Optimization
The future of CFRD treatment likely involves combination approaches that address multiple aspects of the disease simultaneously. This might include CFTR modulators to improve underlying pancreatic function, insulin to replace deficient hormone, medications to reduce insulin resistance when present, anti-inflammatory therapies to reduce pancreatic damage, and potentially regenerative approaches to restore beta-cell mass.
Determining the optimal combination and timing of these therapies for individual patients will require sophisticated clinical trials and real-world evidence studies. The goal is to move beyond one-size-fits-all treatment protocols to truly personalized therapeutic strategies.
Prevention Strategies
Perhaps the most exciting frontier in CFRD research is the possibility of prevention. If we can identify individuals at high risk before significant beta-cell loss occurs, and if we have interventions that can preserve pancreatic function, it may be possible to prevent CFRD altogether or significantly delay its onset.
Potential prevention strategies being investigated include early initiation of CFTR modulators to preserve pancreatic function, anti-inflammatory therapies to reduce pancreatic damage, interventions targeting insulin resistance, and possibly even regenerative approaches to maintain beta-cell mass. Clinical trials are needed to determine which of these approaches are effective and safe for prevention.
The concept of prevention is particularly appealing given that CFRD, once established, requires lifelong treatment and is associated with worse health outcomes. If even a portion of cases could be prevented or significantly delayed, the impact on quality of life and health outcomes would be substantial.
Global Perspectives and Access to Care
While significant advances are being made in CFRD research and treatment, access to these innovations varies widely around the world. Ensuring that all people with CF and CFRD can benefit from emerging treatments is an important challenge facing the global CF community.
Healthcare Disparities
The cost of such treatments remains a challenge, with a patient in the United States requiring Trikafta costing $311,000 a year, putting this drug beyond the economic reach of most people in LMICs and also among the uninsured populations, and the availability of biosimilars together with approaches that aim to lower the cost of treatment will play a crucial role. The high cost of CFTR modulators and other advanced therapies creates significant disparities in access.
Even within developed countries, access to specialized CF care and diabetes management tools varies. People living in rural areas may have limited access to CF centers with expertise in CFRD management. Insurance coverage for continuous glucose monitors, insulin pumps, and other technologies may be limited or unavailable for some patients.
Addressing these disparities requires efforts at multiple levels—from pharmaceutical companies developing more affordable treatments, to healthcare systems ensuring adequate coverage, to advocacy organizations working to expand access to care.
Global Research Collaboration
There are growing pressures on health organizations and pharmaceutical firms to collaborate towards making these life-saving drugs accessible worldwide, and organizations, such as the Cystic Fibrosis Foundation, are conducting further clinical trials and funding research into treatments for CF, aiming at the development of CF treatments to be accessible across the globe. International collaboration in research and care delivery is essential for advancing the field and ensuring equitable access.
Patient registries that collect data from multiple countries provide valuable insights into CFRD epidemiology, treatment patterns, and outcomes across different healthcare systems. These registries enable large-scale research studies that would not be possible within single countries or centers.
International clinical trials and research networks facilitate the development and testing of new treatments, ensuring that diverse populations are represented in research and that findings are applicable globally. Sharing best practices and treatment protocols across countries helps raise the standard of care worldwide.
Living with CFRD: Patient Perspectives and Quality of Life
While medical advances are crucial, understanding the lived experience of people with CFRD is equally important for developing patient-centered care approaches. The daily reality of managing both CF and diabetes significantly impacts quality of life, and addressing these impacts is an essential component of comprehensive care.
Treatment Burden
People with CF already face a substantial treatment burden, spending hours each day on airway clearance, inhaled medications, and other therapies. Adding diabetes management—including blood glucose monitoring, insulin administration, carbohydrate counting, and managing supplies—significantly increases this burden.
How can we assess and improve patient acceptance of the diagnosis of CFRD to improve diabetes self-management and psychosocial well-being? This question recognizes that medical management alone is insufficient—addressing the psychological and practical challenges of living with CFRD is essential for optimal outcomes.
Strategies to reduce treatment burden include simplifying regimens when possible, using technologies that reduce the need for fingerstick glucose testing, providing adequate support for diabetes self-management, and addressing mental health needs. Understanding and minimizing treatment burden is important for improving adherence and quality of life.
Psychosocial Impact
The emotional impact of CFRD should not be underestimated. Many people with CF describe feeling overwhelmed when diagnosed with CFRD, frustrated at having another chronic condition to manage, and anxious about the implications for their health and future. Depression and anxiety are common in people with chronic illnesses, and the combination of CF and diabetes may increase these risks.
Social impacts are also significant. Managing diabetes can affect social activities, particularly those involving food. Young people with CFRD may feel different from their peers, and adults may struggle with the demands of managing both conditions while working, raising families, and maintaining relationships.
Comprehensive CFRD care must address these psychosocial aspects. This includes providing mental health support, connecting patients with peer support resources, helping families adapt to the diagnosis, and working with patients to develop management strategies that fit their lifestyles and priorities.
Empowerment and Self-Management
Despite the challenges, many people with CFRD successfully manage both conditions and maintain good quality of life. Empowering patients with knowledge, skills, and support for self-management is crucial. This includes comprehensive diabetes education, problem-solving skills for managing challenging situations, confidence in adjusting insulin doses, and knowing when to seek help.
Shared decision-making—involving patients in treatment decisions and respecting their preferences and priorities—is important for developing management plans that patients can and will follow. Recognizing patients as experts in their own experience and partnering with them in care planning leads to better outcomes and satisfaction.
Conclusion: A Promising Future for CFRD Management
The landscape of cystic fibrosis-related diabetes is rapidly evolving. From our growing understanding of disease mechanisms to the development of CFTR modulators that address the underlying cause of CF, from advanced diabetes technologies to emerging regenerative therapies, progress is being made on multiple fronts.
Cystic fibrosis-related diabetes (CFRD) is a unique form of diabetes that shares features with both type 1 and type 2 diabetes and is most often characterised by transient postprandial hyperglycaemia as a consequence of delayed first-phase insulin release, and in the last decade, new developments in the form of highly effective modulators have transformed the landscape of cystic fibrosis (CF) care and life expectancy, and as CFRD is one of the most common complications of CF, there is a growing and urgent need to better understand how to optimise CFRD diagnosis and management across the continuum.
The future of CFRD management will likely involve increasingly personalized approaches, combining multiple therapeutic strategies tailored to individual characteristics and needs. Prevention may become possible for some individuals through early intervention with CFTR modulators and other therapies. Advanced technologies will continue to improve glucose monitoring and insulin delivery, reducing treatment burden while improving outcomes.
Research continues to expand our understanding of CFRD pathophysiology, identify biomarkers for early detection, and develop novel therapeutic approaches. Clinical trials are testing new treatments and strategies, and international collaboration is accelerating progress and working to ensure equitable access to advances.
For people living with CFRD today, comprehensive multidisciplinary care that addresses both the medical and psychosocial aspects of the condition can significantly improve quality of life and health outcomes. As research progresses and new treatments emerge, the outlook for people with CFRD continues to improve.
The journey from understanding CFRD as a complication of CF to developing targeted therapies and potentially preventive strategies represents remarkable progress. While challenges remain—including ensuring global access to advanced treatments, reducing treatment burden, and addressing the psychosocial impacts of living with both conditions—the trajectory is clearly positive. With continued research, innovation, and commitment to patient-centered care, the future for people with cystic fibrosis-related diabetes is brighter than ever before.
Additional Resources and Support
For individuals and families affected by CFRD, numerous resources are available to provide information, support, and connection with others facing similar challenges. The Cystic Fibrosis Foundation offers comprehensive information about CFRD, including clinical care guidelines, educational materials, and information about research and clinical trials. Their website provides resources for patients, families, and healthcare providers.
The American Diabetes Association provides general diabetes education and resources that can be helpful for people with CFRD, though it’s important to work with healthcare providers who understand the unique aspects of CFRD. Many CF care centers offer specialized CFRD clinics where patients can receive coordinated care from teams with expertise in both conditions.
Online communities and support groups connect people with CFRD and their families, providing opportunities to share experiences, ask questions, and offer mutual support. These connections can be invaluable for coping with the challenges of managing both conditions and learning practical strategies from others who understand the daily realities of life with CFRD.
As research continues and new treatments emerge, staying informed about advances in CFRD care can help patients and families make informed decisions about their treatment options. Participating in clinical trials, when appropriate, not only provides access to cutting-edge treatments but also contributes to advancing knowledge that will benefit future generations of people with CFRD.
The combination of advancing medical science, improving technologies, comprehensive multidisciplinary care, and strong patient support networks provides a solid foundation for optimizing outcomes and quality of life for people living with cystic fibrosis-related diabetes. While CFRD presents significant challenges, the progress being made offers genuine hope for better management, improved outcomes, and potentially even prevention in the future.